LSTA flags going concern doubt as $5/share Kuva buyout stalls twice, cash halves to $13M

Filed May 11, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Management disclosed substantial doubt about continuing operations for the next 12 months, reversing prior-year assessment that cash was sufficient. Cash fell 50% to $13.1M from $25.8M year-over-year.

  MD&A: Liquidity verify on EDGAR →
• high

  Kuva Labs' $5/share acquisition missed April 3 and April 13 deadlines, now extended to May 29. Company warns the offer may never commence and faces uncertainty collecting $2M termination fee if Kuva walks.

  Controls: Kuva Acquisition Risk verify on EDGAR →
• high

  Terminated Qilu license for Greater China, eliminating up to $200M in potential milestones and 10-15% royalties. Company does not own data from Qilu's completed 96-patient Phase 2 trial.

  MD&A: Qilu Termination verify on EDGAR →